| Anita Lynn Baker-ross, APN, CNM | |
|
1312 Bishop St, Union City, TN 38261-5406 | |
| (731) 885-5150 | |
| (731) 885-7584 |
| Full Name | Anita Lynn Baker-ross |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 18 Years |
| Location | 1312 Bishop St, Union City, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265435671 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | APN11590 (Tennessee) | Primary |
| 367A00000X | Advanced Practice Midwife | 3012814 (Kentucky) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Memorial Medical Group, Inc. | 5193610228 | 433 |
News Archive
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.
Fear of looking unattractive can be a stronger motivation for keeping people going to the gym than the hope of looking good, a study says.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
Kaiser Health News reports on questions resulting from a directive passed last November in Tulsa, Okla. "An elderly woman taken last year to St. John Medical Center in Tulsa, Okla., had suffered a massive stroke and could no longer speak, eat or drink.
› Verified 9 days ago
| Entity Name | Baptist Memorial Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306089206 PECOS PAC ID: 5193610228 Enrollment ID: O20040218000385 |
News Archive
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.
Fear of looking unattractive can be a stronger motivation for keeping people going to the gym than the hope of looking good, a study says.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
Kaiser Health News reports on questions resulting from a directive passed last November in Tulsa, Okla. "An elderly woman taken last year to St. John Medical Center in Tulsa, Okla., had suffered a massive stroke and could no longer speak, eat or drink.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anita Lynn Baker-ross, APN, CNM 965 Ridge Lake Blvd Ste 103, Memphis, TN 38120-9446 Ph: () - | Anita Lynn Baker-ross, APN, CNM 1312 Bishop St, Union City, TN 38261-5406 Ph: (731) 885-5150 |
News Archive
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.
Fear of looking unattractive can be a stronger motivation for keeping people going to the gym than the hope of looking good, a study says.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.
Kaiser Health News reports on questions resulting from a directive passed last November in Tulsa, Okla. "An elderly woman taken last year to St. John Medical Center in Tulsa, Okla., had suffered a massive stroke and could no longer speak, eat or drink.
› Verified 9 days ago
Ms. Tracy Terry Huff, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1312 Bishop St, Union City, TN 38261 Phone: 731-885-5100 |